Revenue that is growing, not promised
FY26 revenue reached A$5.3 million, up 41%, with both established channels contributing: HIV tests up 21% to A$2.8 million and partner supply up 209% to A$2.2 million. Our underlying EBITDA loss narrowed 39% over the same period, so growth is starting to show operating leverage rather than just scale.